Company reiterates commitment to solving some of the toughest
challenges in highly resistant cancers and viruses and developing
better treatments that can make a real impact in people's
lives
HOUSTON, April 14, 2022 /PRNewswire/ -- Moleculin
Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a
clinical stage pharmaceutical company with a broad portfolio of
drug candidates targeting highly resistant tumors and viruses,
today announced the launch its new corporate branding and website
www.moleculin.com.
"As we drive clinical development across our broad portfolio of
drug candidates, expand our growing body of clinical data and build
value among all stakeholders, we believed it was an important step
to refresh our corporate branding identity and website to align
with the true potential and vision we have for Moleculin. We are
wholeheartedly committed to potentially solving some of the
toughest challenges and importantly, bringing better treatments to
patients where there remains unmet medical need. The work completed
and data demonstrated to-date bolsters our confidence as we believe
we can successfully execute on a number of key clinical and
regulatory milestones that will be instrumental in establishing a
clear path to approval and commercialization of Annamycin. I am
excited for this evolution of Moleculin and to take another step
forward towards the future of this exciting company," commented
Walter Klemp, Chairman and CEO of
Moleculin.
The Company's lead product candidate, Annamycin, is a
next-generation anthracycline that has been shown in animal models
to accumulate in the lungs at up to 30-fold the level of
doxorubicin, as well as demonstrating the ability to avoid the
multidrug resistance mechanisms that typically limit the efficacy
of doxorubicin and other currently prescribed anthracyclines.
Importantly, Annamycin has also demonstrated a lack of
cardiotoxicity in multiple human clinical trials, including ongoing
trials for the treatment of relapsed or refractory acute myeloid
leukemia (AML) and soft tissue sarcoma (STS) lung metastases, and
the Company believes that the use of Annamycin may not face the
same usage limitations imposed on doxorubicin, one of the most
common currently prescribed anthracyclines, and may have the
potential to treat a number of additional indications.
Additionally, Moleculin has a robust priority and follow on
pipeline comprised of Immune/Transcription Modulators and a
portfolio of antimetabolites in development for the treatment of a
number of highly resistant tumors and viruses.
For more information about the Company's portfolio of product
candidates and ongoing clinical trials, please visit
www.moleculin.com.
About Moleculin Biotech, Inc.
Moleculin Biotech, Inc. is a clinical stage pharmaceutical
company focused on the development of a broad portfolio of drug
candidates for the treatment of highly resistant tumors and
viruses. The Company's lead program, Annamycin is a next-generation
anthracycline designed to avoid multidrug resistance mechanisms
with little to no cardiotoxicity. Annamycin is currently in
development for the treatment of relapsed or refractory acute
myeloid leukemia (AML) and soft tissue sarcoma (STS) lung
metastases.
Additionally, the Company is developing WP1066, an
Immune/Transcription Modulator capable of inhibiting p-STAT3 and
other oncogenic transcription factors while also stimulating a
natural immune response, targeting brain tumors, pancreatic and
other cancers, and WP1220, an analog to WP1066, for the topical
treatment of cutaneous T-cell lymphoma. Moleculin is also engaged
in the development of a portfolio of antimetabolites, including
WP1122 for the potential treatment of COVID-19 and other viruses,
as well as cancer indications including brain tumors, pancreatic
and other cancers.
For more information about the Company, please visit
www.moleculin.com and connect on Twitter, LinkedIn and
Facebook.
Forward-Looking Statements
Some of the statements in this release are forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933, Section 21E of the Securities Exchange Act of 1934 and the
Private Securities Litigation Reform Act of 1995, which involve
risks and uncertainties. Although Moleculin believes that the
expectations reflected in such forward-looking statements are
reasonable as of the date made, expectations may prove to have been
materially different from the results expressed or implied by such
forward-looking statements. Moleculin has attempted to identify
forward-looking statements by terminology including ''believes,''
''estimates,'' ''anticipates,'' ''expects,'' ''plans,''
''projects,'' ''intends,'' ''potential,'' ''may,'' ''could,''
''might,'' ''will,'' ''should,'' ''approximately'' or other words
that convey uncertainty of future events or outcomes to identify
these forward-looking statements. These statements are only
predictions and involve known and unknown risks, uncertainties, and
other factors, including those discussed under Item 1A. "Risk
Factors" in our most recently filed Form 10-K filed with the
Securities and Exchange Commission ("SEC") and updated from time to
time in our Form 10-Q filings and in our other public filings with
the SEC. Any forward-looking statements contained in this release
speak only as of its date. We undertake no obligation to update any
forward-looking statements contained in this release to reflect
events or circumstances occurring after its date or to reflect the
occurrence of unanticipated events.
Investor Contact:
JTC Team, LLC
Jenene Thomas
(833) 475-8247
MBRX@jtcir.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/moleculin-announces-corporate-rebranding-and-launch-of-new-website-301525473.html
SOURCE Moleculin Biotech, Inc.